Nexalin Technology Inc. (NXL) - Net Assets
Based on the latest financial reports, Nexalin Technology Inc. (NXL) has net assets worth $3.75 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.64 Million) and total liabilities ($887.33K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Nexalin Technology Inc.'s assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.75 Million |
| % of Total Assets | 80.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 24.03 |
Nexalin Technology Inc. - Net Assets Trend (2019–2025)
This chart illustrates how Nexalin Technology Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Nexalin Technology Inc. asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Nexalin Technology Inc. (2019–2025)
The table below shows the annual net assets of Nexalin Technology Inc. from 2019 to 2025. For live valuation and market cap data, see how much is Nexalin Technology Inc. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.75 Million | +1.96% |
| 2024-12-31 | $3.68 Million | +14.64% |
| 2023-12-31 | $3.21 Million | -41.47% |
| 2022-12-31 | $5.48 Million | +425.74% |
| 2021-12-31 | $-1.68 Million | -5.76% |
| 2020-12-31 | $-1.59 Million | -34.85% |
| 2019-12-31 | $-1.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nexalin Technology Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3165737800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.19K | 0.51% |
| Other Comprehensive Income | $406.00 | 0.01% |
| Other Components | $96.60 Million | 2577.27% |
| Total Equity | $3.75 Million | 100.00% |
Nexalin Technology Inc. Competitors by Market Cap
The table below lists competitors of Nexalin Technology Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SWS Capital Bhd
KLSE:7186
|
$7.21 Million |
|
Citra Nusa Holdings Bhd
KLSE:5104
|
$7.21 Million |
|
EverGen Infrastructure Corp
V:EVGN
|
$7.22 Million |
|
AMA Corp PLC
PA:ALAMA
|
$7.22 Million |
|
Iqstel Inc
NASDAQ:IQST
|
$7.20 Million |
|
Silver Elephant Mining Corp
TO:ELEF
|
$7.20 Million |
|
Agri-Tech (India) Limited
NSE:AGRITECH
|
$7.19 Million |
|
Thai Ha Public Company Limited
BK:KASET
|
$7.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nexalin Technology Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,676,038 to 3,747,986, a change of 71,948 (2.0%).
- Net loss of 8,222,181 reduced equity.
- New share issuances of 4,646,397 increased equity.
- Other comprehensive income increased equity by 919.
- Other factors increased equity by 3,646,813.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.22 Million | -219.38% |
| Share Issuances | $4.65 Million | +123.97% |
| Other Comprehensive Income | $919.00 | +0.02% |
| Other Changes | $3.65 Million | +97.3% |
| Total Change | $- | 1.96% |
Book Value vs Market Value Analysis
This analysis compares Nexalin Technology Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.66x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.16 | $0.38 | x |
| 2020-12-31 | $-0.22 | $0.38 | x |
| 2021-12-31 | $-0.23 | $0.38 | x |
| 2022-12-31 | $0.75 | $0.38 | x |
| 2023-12-31 | $0.44 | $0.38 | x |
| 2024-12-31 | $0.40 | $0.38 | x |
| 2025-12-31 | $0.23 | $0.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nexalin Technology Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -219.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2725.76%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.24x
- Recent ROE (-219.38%) is below the historical average (-86.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -2421.22% | 1.84x | 0.00x | $-4.90 Million |
| 2020 | 0.00% | -1401.11% | 2.05x | 0.00x | $-3.24 Million |
| 2021 | 0.00% | -4218.93% | 0.19x | 0.00x | $-5.91 Million |
| 2022 | -30.99% | -128.49% | 0.18x | 1.36x | $-2.25 Million |
| 2023 | -144.97% | -4197.56% | 0.03x | 1.13x | $-4.97 Million |
| 2024 | -206.94% | -4508.73% | 0.04x | 1.15x | $-7.97 Million |
| 2025 | -219.38% | -2725.76% | 0.07x | 1.24x | $-8.60 Million |
Industry Comparison
This section compares Nexalin Technology Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nexalin Technology Inc. (NXL) | $3.75 Million | 0.00% | 0.24x | $7.20 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Nexalin Technology Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Genera… Read more